Generic Tryptyr Availability
Last updated on Jul 9, 2025.
Tryptyr is a brand name of acoltremon ophthalmic, approved by the FDA in the following formulation(s):
TRYPTYR (acoltremon - solution/drops;ophthalmic)
-
Manufacturer: ALCON LABS INC
Approval date: May 28, 2025
Strength(s): 0.003% [RLD]
Is there a generic version of Tryptyr available?
No. There is currently no therapeutically equivalent version of Tryptyr available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tryptyr. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods for treating occular irritation involving tearing by administering modulators of TRPM8
Patent 10,028,920
Issued: July 24, 2018
Inventor(s): Belmonte Martínez; Carlos et al.
Assignee(s): UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (Elche, ES); CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFÍCAS C.S.I.C. (Madrid, ES)The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.
Patent expiration dates:
- September 8, 2031✓
- September 8, 2031
-
Ophthalmic pharmaceutical compositions and uses thereof
Patent 11,850,221
Issued: December 26, 2023
Inventor(s): Joshi; Anjali
Assignee(s): Aerie Pharmaceuticals, Inc. (Bedminster, NJ)Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.
Patent expiration dates:
- December 16, 2042✓✓
- December 16, 2042
-
Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia
Patent 9,095,609
Issued: August 4, 2015
Inventor(s): Belmonte Martnez; Carlos et al.
Assignee(s): UNIVERSIDAD MIGUEL HERN NDEZ DE ELCHE (N/A, ES); CONSEJO SUPERIOR DE INVESTIGACIONES CIENT FICAS (C.S.I.C.) (N/A, ES)The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.
Patent expiration dates:
- September 8, 2031✓✓
- September 8, 2031
-
Use of TRMP8 for treating opthalmic diseases or conditions involving tearing
Patent 9,433,679
Issued: September 6, 2016
Inventor(s): Belmonte Martínez; Carlos et al.
Assignee(s): UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (Elche, ES); CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (C.S.I.C.) (Madrid, ES)The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.
Patent expiration dates:
- September 8, 2031✓
- September 8, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 28, 2030 - NEW CHEMICAL ENTITY
More about Tryptyr (acoltremon ophthalmic)
- Compare alternatives
- Drug images
- Dosage information
- FDA approval history
- Drug class: miscellaneous ophthalmic agents
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
